EPISODE · Feb 3, 2026 · 35 MIN
This CEO Wants To Save Lives, Is Fighting ALS, & Wants Your Brain To Be Healthier
from Smart Money Circle · host Adam Sarhan
This CEO Wants To Save Lives, Is Fighting ALS, & Wants Your Brain To Be Healthier GuestRob Etherington, CEO and President of Clene Inc.Clene Inc. https://clene.comTicker: CLNNBioMr. Etherington is the CEO of Clene, Inc (NASDAQ: CLNN). Clene is a platform company leading the way in drug nanotherapeutics, with multiple Phase 2 and one Phase 3 registration study presently underway in the field of neurodegenerative disease (ALS, Multiple Sclerosis, Parkinson’s). Rob has privately raised over $160M (over $146M in equity and over $18M in grant/indirect support) for Clene, and took Clene public on the NASDAQ in late 2020. Before joining Clene as its founding CEO in 2013, Mr. Etherington worked for Actelion Pharmaceuticals, which was the largest biopharmaceutical company based in the EU until Johnson &Johnson Pharmaceuticals acquired the company in 2017. He initially joined Actelion as founding Director of Marketing in 2000 (the same year the company went public) and went on to hold various roles of increasing responsibility, including as Head of U.S. commercial operations and serving as Chair of the U.S. Commercial Strategic team with responsibility for five marketed drugs. Prior to Actelion, Mr. Etherington began his pharmaceutical career with a number of sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in one of the Team Leader positions that oversaw the drug Lipitor.About CleneClene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
What this episode covers
This CEO Wants To Save Lives, Is Fighting ALS, & Wants Your Brain To Be Healthier GuestRob Etherington, CEO and President of Clene Inc.Clene Inc. https://clene.comTicker: CLNNBioMr. Etherington is the CEO of Clene, Inc (NASDAQ: CLNN). Clene is a platform company leading the way in drug nanotherapeutics, with multiple Phase 2 and one Phase 3 registration study presently underway in the field of neurodegenerative disease (ALS, Multiple Sclerosis, Parkinson’s). Rob has privately raised over $160M (over $146M in equity and over $18M in grant/indirect support) for Clene, and took Clene public on the NASDAQ in late 2020. Before joining Clene as its founding CEO in 2013, Mr. Etherington worked for Actelion Pharmaceuticals, which was the largest biopharmaceutical company based in the EU until Johnson &Johnson Pharmaceuticals acquired the company in 2017. He initially joined Actelion as founding Director of Marketing in 2000 (the same year the company went public) and went on to hold various roles of increasing responsibility, including as Head of U.S. commercial operations and serving as Chair of the U.S. Commercial Strategic team with responsibility for five marketed drugs. Prior to Actelion, Mr. Etherington began his pharmaceutical career with a number of sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in one of the Team Leader positions that oversaw the drug Lipitor.About CleneClene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
NOW PLAYING
This CEO Wants To Save Lives, Is Fighting ALS, & Wants Your Brain To Be Healthier
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.